Delving into the Latest Updates on Surio Therapeutics Co., Ltd. with Synapse

Overview

Tags

Neoplasms

Urogenital Diseases

Digestive System Disorders

Chemical drugs

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	6
Endocrinology and Metabolic Disease	3
Infectious Diseases	1

Top 5 Drug Type	Count

Chemical drugs	4
Small molecule drug	2

Top 5 Target	Count

ALDH(Aldehyde dehydrogenases)	1
Top I(DNA topoisomerase I)	1
Tubulin	1

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 20 Mar 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

2

Preclinical

IND Approval

2

1

Phase 1

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

ST114	Advanced Malignant Solid Neoplasm More	IND Approval
SURIO-001 ( Tubulin )	Advanced Malignant Solid Neoplasm More	IND Approval
ST205 ( Tubulin )	Advanced Malignant Solid Neoplasm More	IND Approval
SURIO-002 ( Top I )	Non-Small Cell Lung Cancer More	Preclinical
SURIO-003	Neoplasms More	Preclinical